Mycenax Biotech Past Earnings Performance
Past criteria checks 0/6
Mycenax Biotech's earnings have been declining at an average annual rate of -35.4%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 15.9% per year.
Key information
-35.4%
Earnings growth rate
-19.5%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 15.9% |
| Return on equity | -27.9% |
| Net Margin | -104.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Mycenax Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 653 | -683 | 151 | 76 |
| 30 Sep 23 | 666 | -713 | 164 | 106 |
| 30 Jun 23 | 712 | -764 | 216 | 126 |
| 31 Mar 23 | 645 | -713 | 189 | 139 |
| 31 Dec 22 | 732 | -454 | 187 | 144 |
| 30 Sep 22 | 757 | -327 | 138 | 126 |
| 30 Jun 22 | 752 | -233 | 149 | 116 |
| 31 Mar 22 | 708 | -186 | 131 | 103 |
| 31 Dec 21 | 774 | -90 | 127 | 96 |
| 30 Sep 21 | 732 | -46 | 111 | 77 |
| 30 Jun 21 | 725 | 19 | 104 | 57 |
| 31 Mar 21 | 888 | 167 | 116 | 52 |
| 31 Dec 20 | 665 | 31 | 105 | 47 |
| 30 Sep 20 | 619 | 1 | 97 | 105 |
| 30 Jun 20 | 548 | -79 | 93 | 184 |
| 31 Mar 20 | 394 | -188 | 84 | 230 |
| 31 Dec 19 | 391 | -218 | 78 | 285 |
| 30 Sep 19 | 346 | -268 | 72 | 337 |
| 30 Jun 19 | 327 | -231 | 72 | 301 |
| 31 Mar 19 | 260 | -256 | 61 | 311 |
| 31 Dec 18 | 211 | -274 | 61 | 276 |
| 30 Sep 18 | 218 | -296 | 64 | 227 |
| 30 Jun 18 | 285 | -219 | 62 | 216 |
| 31 Mar 18 | 311 | -186 | 65 | 190 |
| 31 Dec 17 | 319 | -188 | 66 | 195 |
| 30 Sep 17 | 299 | -96 | 59 | 191 |
| 30 Jun 17 | 260 | -142 | 50 | 214 |
| 31 Mar 17 | 216 | -171 | 45 | 217 |
| 31 Dec 16 | 201 | -158 | 41 | 218 |
| 30 Sep 16 | 185 | -153 | 36 | 196 |
| 30 Jun 16 | 155 | -133 | 33 | 170 |
| 31 Mar 16 | 133 | -134 | 35 | 154 |
| 31 Dec 15 | 135 | -111 | 33 | 145 |
| 30 Sep 15 | 130 | -91 | 33 | 144 |
| 30 Jun 15 | 84 | -126 | 34 | 143 |
| 31 Mar 15 | 120 | -80 | 29 | 148 |
| 31 Dec 14 | 113 | -87 | 28 | 149 |
| 30 Sep 14 | 99 | -100 | 30 | 139 |
| 30 Jun 14 | 97 | -90 | 29 | 131 |
| 31 Mar 14 | 68 | -100 | 30 | 116 |
| 31 Dec 13 | 64 | -89 | 30 | 103 |
| 30 Sep 13 | 49 | -88 | 30 | 101 |
| 30 Jun 13 | 44 | -99 | 30 | 106 |
Quality Earnings: 4726 is currently unprofitable.
Growing Profit Margin: 4726 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4726 is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.
Accelerating Growth: Unable to compare 4726's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4726 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 4726 has a negative Return on Equity (-27.9%), as it is currently unprofitable.